LJI308/ supplier with competitive price in stock-Rechems

Details:

LJI308 is a new and potent pan-RSK inhibitor, with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.IC50 value: 6/4/13 nM Target: RSK1/2/3 in vitro: LJI308 efficiently inhibits RSK activity.LJI308 inhibites S6K1 with an IC50 of 0.8 μM, representing a 200-fold lower inhibition than that of RSK2.LJI308 inhibits MEK4 less than 50% at 10 μMand HIP kinase 1 less than 50% at 1 μM.LJI308 inhibits the growth and survival of TNBC.LJI308 also suppresses the growth of HTRY-LT cells in 3-dimensional soft agar cultures.LJI308 is one of the first potent and effective targeted therapies for TNBC that, unlike currently utilized drugs, exhibits efficacy in eliminating the CSC population.
Shanghai Rechem science Co., Ltd.
Rechemsis focus on R&D of new APIS, signal transduction inhibitors and pharmaceutical intermediates. We follow closely the industry trend, and the latest research achievements in life science area.
Rechems is located in the largest biomedical base in China--Shanghai and cooperatively established modern production base and laboratory in surrounding areas. We have built up a good relationship with many US / European / Japanese pharmaceutical companies to conduct chemical research and inventory trading in medicinal chemistry.
Rechems's mission is to serve pharmaceutical community by providing excellent services and high-quality products in a timely manner.
Rechems's vision is to be recognized by our clients as one of the best suppliers of chemical products for our superior quality, efficient and cost-effective services.
We insist the principle of "Quality first, customer foremost, best credit, be pioneering and creative", looking forward to establishing good business relationships with customers all over the world. Let's work together for bright future!